Ras inhibition via direct Ras binding--is there a path forward?

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The Ras oncogene, identified over 30 years ago, drives numerous human cancers.
• Despite extensive drug discovery efforts, effective therapies targeting Ras-mutant tumors are still lacking.

Purpose of the Study:

• To critically review strategies for inhibiting Ras function through direct small molecule binding.
• To identify key challenges and propose future directions for developing Ras-targeting therapeutics.

Main Methods:

• Review of literature on small molecules designed to bind directly to the Ras protein surface.
• Analysis of structural data from Ras-binder complexes.
• Evaluation of biochemical and biophysical studies on Ras-inhibitor interactions.

Main Results:

• Multiple Ras binders targeting different sites have been identified, with some exhibiting inhibitory activity.
• Disruption of the Ras-SOS interaction, leading to inhibition of nucleotide exchange, is a common mode of action.
• Current binders often possess low binding affinities and lack selectivity for mutant Ras over wild-type Ras or other GTPases.

Conclusions:

• Enhancing binding affinity and achieving selectivity are critical challenges for developing effective Ras inhibitors.
• Continued exploration of functionally active Ras binders, utilizing integrated biophysical and biochemical tools, is encouraged.
• Collaborative efforts between industry and academia are proposed to overcome the significant hurdles in Ras-targeted drug development.